Bryostatin-1 is under clinical development by Synaptogenix and currently in Phase I for Multiple Sclerosis. According to GlobalData, Phase I drugs for Multiple Sclerosis have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Bryostatin-1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Bryostatin-1 overview

Bryostatin-1 is under development for the treatment of amyotrophic lateral sclerosis (ALS), multiple sclerosis, depression, Parkinson's disease, Fragile X Syndrome (FXS), Rett syndrome, stroke, traumatic brain injury and Niemann-Pick type C. It is administered as an intravenous infusion. The drug candidate belongs to family of natural marine cyclic macrolides. It acts by targeting protein kinase C (PKC isozymes).

It was under development for the treatment of Alzheimer's disease, relapsed and refractory acute lymphoblastic leukemia, lymphoma.

Synaptogenix overview

Synaptogenix is a biotechnology company that focuses on developing new approaches to treat neurodegenerative diseases. It is developing Bryostatin-1, a potent modulator of protein kinase –C to delay or prevent the progression of Alzheimer’s disease (AD). The company also evaluates the product for rare diseases and also other neurodegenerative diseases including brain injury-related diseases such as Fragile X syndrome, multiple sclerosis, stroke, Niemann-Pick Type C disease, Parkinson’s disease, Rett syndrome and traumatic brain injury. Synaptogenix is headquartered in New York, the US.

For a complete picture of Bryostatin-1’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.